Immune thrombocytopenia treatment has evolved recently. However, none of treatments have only
benefits without drawbacks. This study compares the clinical outcomes and adverse drug
patterns of different treatment options. Medications which will be assessed during the
current study are High Dose-dexamethasone (HD-DXM) (control group), Prednisolone +
Azathioprine, Rituximab, Eltrombopag, and Romiplostim.